Johnson & Johnson (JNJ) : Garcia Hamilton Associates Lpde reduced its stake in Johnson & Johnson by 7.98% during the most recent quarter end. The investment management company now holds a total of 57,915 shares of Johnson & Johnson which is valued at $7,136,286 after selling 5,020 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.Johnson & Johnson makes up approximately 4.10% of Garcia Hamilton Associates Lpde’s portfolio.
Other Hedge Funds, Including , Columbia Partners L L C Investment Management reduced its stake in JNJ by selling 2,258 shares or 1.65% in the most recent quarter. The Hedge Fund company now holds 134,836 shares of JNJ which is valued at $16,614,492. Johnson & Johnson makes up approx 1.18% of Columbia Partners L L C Investment Management’s portfolio.Baillie Gifford Co boosted its stake in JNJ in the latest quarter, The investment management firm added 58,245 additional shares and now holds a total of 243,622 shares of Johnson & Johnson which is valued at $30,153,095. Johnson & Johnson makes up approx 0.05% of Baillie Gifford Co’s portfolio.Douglas Lane Associates reduced its stake in JNJ by selling 1,545 shares or 1.8% in the most recent quarter. The Hedge Fund company now holds 84,125 shares of JNJ which is valued at $10,496,276. Johnson & Johnson makes up approx 0.28% of Douglas Lane Associates’s portfolio.Bristol John W Co Inc Ny reduced its stake in JNJ by selling 127,013 shares or 6.27% in the most recent quarter. The Hedge Fund company now holds 1,897,563 shares of JNJ which is valued at $233,665,908. Johnson & Johnson makes up approx 6.36% of Bristol John W Co Inc Ny’s portfolio.
Johnson & Johnson (JNJ) witnessed a volatile trading activity on Friday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $119.91 and reached the intraday high at $119.99. The bulls started the profit booking and pushed the shares to intraday low of $119.32. The trading session was marked by a volume range of 77,98,299 shares exchanging hands. The 52-week high of the shares is $126.07 and the 52-week low is $81.79. The market cap of the company stands at $328,086 M and there are 2,73,58,76,800 shares in public circulation.
On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.